01104nam--2200373---450-99000194371020331620050606115225.0000194371USA01000194371(ALEPH)000194371USA0100019437120040820d1976----km-y0itay0103----baengGB||||||||001yyWorks and correspondenceAdam SmithOxfordClarendon Press1976v.19..<<Vol. 1.>> : 544 p. ; <<Vol. 2.>> : VII, 545-1080 P.20012001001-------2001SMITH,Adam71866ITsalbcISBD990001943710203316II.1.C. 569/1(IV A Coll. 179/1)L.M.IV AII.1.C. 569/1a(IV A Coll 179/1Bis)76560 LMIV AII.1.C. 569/1b(IV A Coll 179/2 I)70264 LMIV ABKUMASIAV21020040820USA011037COPAT59020050606USA011152Works and correspondence1045321UNISA02735nam 2200613 a 450 991014127220332120200520144314.01-280-59148-X97866136213131-118-26589-01-118-26675-71-118-26679-X(CKB)2670000000175224(EBL)832587(OCoLC)787842613(SSID)ssj0000639670(PQKBManifestationID)11401942(PQKBTitleCode)TC0000639670(PQKBWorkID)10605127(PQKB)10764483(MiAaPQ)EBC832587(Au-PeEL)EBL832587(CaPaEBR)ebr10558697(CaONFJC)MIL362131(OCoLC)797824835(PPN)17900171X(EXLCZ)99267000000017522420111004d2012 uy 0engur|n|---|||||txtccrPharmaceutical lifecycle management[electronic resource] making the most of each and every brand /Tony Ellery, Neal HansenHoboken, N.J. John Wiley & Sonsc20121 online resource (413 p.)Includes index.0-470-48753-4 pt. A. Lifecycle management business environment -- pt. B. Lifecycle management regulatory and legal environment -- pt. C. Patents and exclusivities -- pt. D. Developmental LCM -- pt. E. Commercial LCM -- pt. F. Biologics and biosimilars -- pt. G. The integrated brand LCM strategy and its implementation -- pt. H. Integrating LCM with portfolio management. A comprehensive guide to optimizing the lifecycle management of pharmaceutical brands The mounting challenges posed by cost containment policies and the prevalence of generic alternatives make optimizing the lifecycle management (LCM) of brand drugs essential for pharmaceutical companies looking to maximize the value of their products. Demonstrating how different measures can be combined to create winning strategies, Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand explores this increasingly important field to help readers understand what theyPharmaceutical industryEconomic aspectsDrug approvalEconomic aspectsPharmaceutical industryEconomic aspects.Drug approvalEconomic aspects.338.4/76153Ellery Tony918659Hansen Neal918660MiAaPQMiAaPQMiAaPQBOOK9910141272203321Pharmaceutical lifecycle management2060233UNINA